InflaRx
- Biotech or pharma, therapeutic R&D
InflaRx develops new first-in-class complement therapeutics in the field of life threatening and debilitating rare inflammatory diseases. InflaRx takes a global lead position in targeted complement C5a inhibition.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}